MLTX Latest Headlines

MoonLake Immunotherapeutics: Fast-Track Sonelokimab and Multi-Indication Late-Stage Catalysts Underpin Buy Rating and $32 Target

at www.tipranks.com (Tue, 3-Feb 6:26 AM)

Fast Track Designation Positions MoonLake’s Sonelokimab for Accelerated Path in PPP as Major 2026 Milestones Approach

Market Chameleon (Mon, 2-Feb 8:42 AM)

MoonLake’s Regulatory Win Paves Way for BLA Submission—What Does This Mean for MLTX’s Future?

Market Chameleon (Fri, 9-Jan 11:51 AM)

MoonLake’s Regulatory Milestone Clears the Path for Sonelokimab BLA: What’s Next for MLTX Investors?

Market Chameleon (Thu, 8-Jan 10:32 AM)

FDA Feedback Clears Path for MoonLake’s Sonelokimab—No Additional Trials Needed for HS Application

Market Chameleon (Thu, 8-Jan 8:37 AM)

Shareholder Lawsuit Highlights Questions Over MoonLake’s Lead Drug Claims

Market Chameleon (Thu, 4-Dec 10:54 AM)